

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



国药集团
SINOPHARM

國藥控股股份有限公司 SINOPHARM GROUP CO. LTD.*

(A joint stock limited company incorporated in the People's Republic of China with limited liability and carrying on business in Hong Kong as 國控股份有限公司)
(Stock Code: 01099)

ANNOUNCEMENT PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF SINOPHARM (CNCM LTD) FOR THE NINE MONTHS ENDED 30 SEPTEMBER 2024

This announcement is made pursuant to Rule 13.09 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited and Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

Reference is made to the overseas regulatory announcement of Sinopharm Group Co. Ltd. (the “**Company**”) dated 23 October 2024 (the “**Announcement**”) in relation to the third quarterly report of China National Medicines Corporation Ltd. (國藥集團藥業股份有限公司) (“**SINOPHARM (CNCM LTD)**”), a subsidiary of the Company and whose A shares are listed on the Shanghai Stock Exchange (stock code: 600511).

The board of directors of the Company would like to draw the attention of its shareholders and the public investors to the following principal unaudited accounting data and financial indicators of SINOPHARM (CNCM LTD) for the nine months ended 30 September 2024 as set out in the Announcement.

** The Company is registered as a non-Hong Kong company under the Hong Kong Companies Ordinance under its Chinese name and the English name “Sinopharm Group Co. Ltd.”.*

**PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS OF
SINOPHARM (CNCM LTD)**

*Unit: Yuan
Currency: RMB*

	Reporting Period (Single Quarter)	Changes of the Reporting Period over the same period of last year (%)	From the beginning of the year to the end of the Reporting Period	Changes of the period from the beginning of the year to the end of the Reporting Period over the same period of last year (%)
Revenue	13,272,036,678.02	7.12	38,028,539,709.49	4.10
Net profit attributable to shareholders of the listed company	480,761,109.75	0.64	1,481,271,832.85	1.30
Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses	485,951,905.72	1.22	1,489,051,562.88	4.04
Net cash flow arising from operating activities	N/A	N/A	-1,029,844,632.09	-11,267.47
Basic earnings per share (Yuan/share)	0.6371	0.64	1.9632	1.30
Diluted earnings per share (Yuan/share)	0.6371	0.64	1.9632	1.30
Weighted average return on net assets (%)	2.94	Decreased by 0.28 percentage point	9.17	Decreased by 0.4 percentage point

	At the end of the Reporting Period	At the end of last year	Changes of the end of the Reporting Period over the end of last year (%)
Total assets	34,336,033,546.56	32,453,092,592.42	5.80
Equity attributable to shareholders of the listed company	16,608,250,755.72	15,775,887,678.80	5.28

Note: "Reporting Period" refers to the three months ended 30 September 2024.

INFORMATION ON PRINCIPAL UNAUDITED ACCOUNTING DATA AND FINANCIAL INDICATORS

The decrease in net cash flow arising from operating activities of 11,267.47% was mainly due to the impact of the market environment this year, the delay in the cycle of collection of payments from certain customers, the increase in payment pressure for volume-based procurement, and the adjustments in financing structure.

By order of the Board
Sinopharm Group Co. Ltd.
Zhao Bingxiang
Chairman

Shanghai, the PRC
23 October 2024

As at the date of this announcement, the executive director of the Company is Mr. Lian Wanyong; the non-executive directors of the Company are Mr. Zhao Bingxiang, Mr. Chen Qiyu, Mr. Wang Kan, Mr. Wang Peng, Mr. Wen Deyong, Mr. Li Dongjiu and Ms. Feng Rongli; and the independent non-executive directors of the Company are Mr. Chen Fangruo, Mr. Li Peiyu, Mr. Wu Tak Lung, Mr. Yu Weifeng and Mr. Shi Shenghao.